title: [Antimycotic therapy].
abstract: Because deep opportunistic mycoses are relatively rare, clinicians frequently lack routine in the application of antimycotics. It is the purpose of this review to summarize, from a practical point of view, rationale, indications, applications and toxicity of antimycotic therapy for the mycoses autochthonous to Europe. Amphotericin B remains the standard therapy for most deep opportunistic mycoses, while the newer azoles are the first line agents to be used for superficial forms of candidiasis.
authors.affiliation: Medizinische Universitätsklinik, Departement für Innere Medizin, Universitätsspital Zürich.
authors.forename: A
authors.initials: A
authors.lastname: Schaffner
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000188:drug therapy
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D000666:Amphotericin B
vernacular_title: Antimykotische Therapie.